Deal Snapshot
Kedrion Biopharma Closes Acquisition of Prometic Life Science Business
Wednesday 20 October 2021

Italian biopharmaceuticals company Kedrion Biopharma has closed the acquisition of the Prometic life science business of Canadian biopharmaceutical company Liminal BioSciences, the company said.

In May, Italian biopharmaceuticals company Kedrion Biopharma and Canadian biopharmaceutical company Liminal BioSciences agreed a deal for the sale from Liminal BioSciences to Kedrion of two plasma collection centers, one operated in Winnipeg (Manitoba, Canada) and one in Amherst (New York, USA) through Liminal BioSciences' subsidiaries, Prometic Plasma Resources Inc., and Prometic Plasma Resources (USA) Inc.

Date Published: 20/10/2021